Frequency of T-cell FoxP3+ Treg and CD4+/CD8+ PD-1 expression is related to HBeAg seroconversion in hepatitis B patients on pegylated interferon

Chinese Medical Journal

Volumn 126, Issue 2, 2013, Pages 267-273

  Ma, Hui ^a   Zhang, Heng Hui ^b   Wei, Lai ^b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Cell; Chronic hepatitis B; Dendritic cells; Pegylated interferon and alpha; 2b; Programmed death 1; Regulatory

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; HEPATITIS B (E) ANTIGEN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; MALE; MYELOID DENDRITIC CELL; PLASMACYTOID DENDRITIC CELL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SEROCONVERSION;

ADULT; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HEPATITIS B; HEPATITIS B E ANTIGENS; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECOMBINANT PROTEINS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 84872743632     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20120535     Document Type: Article

References (30)

1. Lok AS, McMahon BJ. Chronic hepatitis B. AASLD practice guidelines. Hepatology 2007; 45: 507-539.
2. Li XD, Wang L, Liu Y, Xu ZH, Dai JZ, Li L, et al. Characterization of hepatitis B virus genotypes/subgenotypes in 1301 patients with chronic hepatitis B in North China. Chin Med J 2011; 124: 4178-4183.
3. Chen GC, Yu T, Huang KH, Chen QK. Antiviral therapy of decompensated hepatitis B virus-related cirrhosis. Chin Med J 2012; 125: 373-377.
4. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinicalconsequences. N Engl J Med 2004; 350: 1118-1129.
5. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-1075.
6. Liaw YF. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma. Semin Liver Dis 2005; 25: 40-47.
7. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol Mech Dis 2006; 1: 23-61.
8. Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, Missale G, et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003; 39: 595-605.
9. Stoop JN, van der Molen RG, Kuipers EJ, Kusters JG, Janssen HL. Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology 2007; 361: 141-148.
10. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14: 778-809.
11. Levy DE, Garcia-Sastre A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev 2001; 12: 143-156.
12. Biron CA. Interferons alpha and beta as immune regulators-a new look. Immunity 2001; 14: 661-664.
13. Grander D, Sangfelt O, Erickson S. How does interferon exert its cell growth inhibitory effect? Eur J Haematol 1997; 59: 129-135.
14. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119: 312-323.
15. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
16. Zhang Z, Zhang HF, Chen DW, Yao JX, Fu JL, Jin L, et al. Response to interferon-α treatment correlates with recovery of blood plasmacytoid dendritic cells in children with chronic hepatitis B. J Hepatol 2007; 47: 751-759.
17. high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245-1253.
18. + T cells with regulatory properties from human blood. J Exp Med 2001; 193: 1303-1310.
19. + T cell activation. Eur J Immunol 2003; 33: 3473-3483.
20. + regulatory T cells suppress NKT cell functions. Cancer Res 2003; 63: 4516-4520.
21. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11: 3887-3895.
22. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27: 195-201.
23. Evans A, Riva A, Cooksley H, Phillips S, Puranik S, Nathwani A, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology 2008; 48: 759-769.
24. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-129.
25. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. New Engl J Med 1990; 323: 295-301.
26. Lok AS, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-2097.
27. van der Molen RG, Sprengers D, Biesta PJ, Kusters JG, Janssen HL. Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. Hepatology 2006; 44: 907-914.
28. Yan T, Wang HF, Ji W, Zhang AM, Zhang Z, Zhang H, et al. Clinical profiles of circulating dendritic cell subsets in chronically HBV-infected patients with interferon-α treatment. Natl Med J China (Chin) 2005; 85: 1177-1181.
29. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47: 428-434.
30. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 73-82.